SBH
NBIX icon

Segall Bryant & Hamill’s Neurocrine Biosciences NBIX Stock Holding History

Segall Bryant & Hamill’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
64,908
+7,974
+14% +$1.18M 0.13% 238
2026
Q1 		$7.5M Buy
56,934
+464
+0.8% +$61.6K 0.11% 256
2025
Q4 		$8.01M Buy
56,470
+1,996
+4% +$289K 0.11% 258
2025
Q3 		$7.65M Buy
54,474
+9,383
+21% +$1.27M 0.1% 267
2025
Q2 		$5.67M Sell
45,091
-8,012
-15% -$919K 0.08% 300
2025
Q1 		$5.87M Buy
53,103
+6,233
+13% +$790K 0.09% 288
2024
Q4 		$6.4M Buy
46,870
+10,398
+29% +$1.29M 0.09% 295
2024
Q3 		$4.2M Sell
36,472
-512
-1% -$70.2K 0.06% 354
2024
Q2 		$5.09M Buy
36,984
+16,908
+84% +$2.32M 0.09% 289
2024
Q1 		$2.77M Buy
+20,076
New +$2.74M 0.05% 271

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Segall Bryant & Hamill's NBIX Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Neurocrine Biosciences (NBIX) stake by 14% in Q2 2026, buying an estimated $1.18M and bringing the position to 64,908 shares worth $10.9M. The position accounts for 0.13% of the portfolio, ranked #238.

Segall Bryant & Hamill first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Segall Bryant & Hamill held 64,908 shares of Neurocrine Biosciences worth $10.9M as of Q2 2026.
  • Segall Bryant & Hamill bought 7,974 Neurocrine Biosciences shares in Q2 2026, an estimated $1.18M.
  • Neurocrine Biosciences made up 0.13% of Segall Bryant & Hamill's portfolio in Q2 2026, its #238 holding.
  • Segall Bryant & Hamill first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.